Alzheimer's Drug Development
.
Alzheimer's Donation
Donate Online Now
Junk-free tops Mintels 2008 food trends
Cutting out the junk will be a major for manufacturers in 2008 said Mintel in its prediction of trends to shape food for the next 12 months, as consumers buy into natural and environmentally-friendly products.
posted YVN
.
Alzheimer's Donation
Donate Online Now
.
EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) announced that Sharon Shacham, Ph.D., vice president of drug development of EPIX, will present "PRX-03140, A Novel and Selective 5-HT4 Agonist for the Treatment of Alzheimer's Disease" at CBI's Alzheimer's Drug Development Summit on Friday, November 30, 2007 at 11:00AM EST in Arlington, Virginia.
This presentation will focus on clinical progress to date for PRX-03140, the company's novel, highly selective, small-molecule agonist of a specific GPCR known as 5-HT4 for the treatment of Alzheimer's disease. EPIX has completed two Phase 1 trials in healthy adults and elderly volunteers as well as a Phase 1b study in patients with Alzheimer's disease. Currently in a Phase 2a clinical trial as a single agent and in combination with Aricept(R) in patients with mild Alzheimer's disease, PRX-03140 is one of the GPCR programs included in the worldwide multi-target strategic collaboration between EPIX and GlaxoSmithKline. EPIX recently completed enrollment of this Phase 2a trial and reaffirmed that it is on track to announce the findings of this study by the end of 2007.
PRX-03140 is EPIX's second of four clinical drug candidates discovered utilizing its proprietary computer-based G-Protein Coupled Receptors (GPCR) models and optimized with integrated computational-medicinal chemistry. PRX-03140 is selective for the 5-HT4 receptor in the brain, and preclinical studies have shown that it improves cognitive function, as well as increases levels of acetylcholine, soluble amyloid precursor protein (sAPP) and brain-derived neurotrophic factor (BDNF) in regions of the brain known to be important for memory. http://www.worldhealth.net
EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) announced that Sharon Shacham, Ph.D., vice president of drug development of EPIX, will present "PRX-03140, A Novel and Selective 5-HT4 Agonist for the Treatment of Alzheimer's Disease" at CBI's Alzheimer's Drug Development Summit on Friday, November 30, 2007 at 11:00AM EST in Arlington, Virginia.
This presentation will focus on clinical progress to date for PRX-03140, the company's novel, highly selective, small-molecule agonist of a specific GPCR known as 5-HT4 for the treatment of Alzheimer's disease. EPIX has completed two Phase 1 trials in healthy adults and elderly volunteers as well as a Phase 1b study in patients with Alzheimer's disease. Currently in a Phase 2a clinical trial as a single agent and in combination with Aricept(R) in patients with mild Alzheimer's disease, PRX-03140 is one of the GPCR programs included in the worldwide multi-target strategic collaboration between EPIX and GlaxoSmithKline. EPIX recently completed enrollment of this Phase 2a trial and reaffirmed that it is on track to announce the findings of this study by the end of 2007.
PRX-03140 is EPIX's second of four clinical drug candidates discovered utilizing its proprietary computer-based G-Protein Coupled Receptors (GPCR) models and optimized with integrated computational-medicinal chemistry. PRX-03140 is selective for the 5-HT4 receptor in the brain, and preclinical studies have shown that it improves cognitive function, as well as increases levels of acetylcholine, soluble amyloid precursor protein (sAPP) and brain-derived neurotrophic factor (BDNF) in regions of the brain known to be important for memory. http://www.worldhealth.net
Cutting out the junk will be a major for manufacturers in 2008 said Mintel in its prediction of trends to shape food for the next 12 months, as consumers buy into natural and environmentally-friendly products.
posted YVN
posted by Valery Yermalitsky at
8:02 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home